{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-017739","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.884431+00:00","generated_at":"2026-06-13T23:10:08.880107+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clene raises $40M in public offering of common stock and warrants; net ~$37.4M for CNM-Au8","bullets":["Offers 50M shares + 50M Tranche A warrants ($1.10 strike) + 50M Tranche B warrants ($1.50 strike) at $0.80/unit.","Gross proceeds ~$40M; estimated net ~$37.4M after discounts and expenses.","Warrant expiration tied to FDA NDA acceptance (Tranche A) or approval (Tranche B), with final dates 2026/2030.","Proceeds to fund CNM-Au8 clinical trials, regulatory filings, commercialization, and general corporate purposes.","Closing expected June 21, 2023; Canaccord Genuity sole bookrunner, Maxim Group and EF Hutton co-managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-017739","json":"https://secwatch.observer/filing/0001437749-23-017739.json","markdown":"https://secwatch.observer/filing/0001437749-23-017739.md","text":"https://secwatch.observer/filing/0001437749-23-017739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923017739/0001437749-23-017739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923017739/clnn20230612_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:10:08.880107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c57c122acff2ac75d4a20679386c1ee9cc1de2ff","claim":"Clene Inc. entered into Underwriting Agreement with Canaccord Genuity LLC (effective 2023-06-16).","evidence_excerpt":"On June 16, 2023, Clene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Canaccord Genuity LLC (“Canaccord”) as underwriter, pursuant to which the Company agreed to issue and sell, in an equity offering (the “Offering”), an aggregate of (i) 50,000,000 shares of its common stock, par value $0.0001 per share (“Common Stock”), (ii) warrants to purchase up to 50,000,000 shares of Common Stock at an exercise price of $1.10 per whole share of Common Stock (the “Tranche A Warrants”), and (iii) warrants to purchase up to 50,000,000 shares of Common Stock at an exercise price of $1.50 per whole share of Common Stock (the “Tranche B Warrants,” and collectively with the Tranche A Warrants, the “Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774923017739/0001437749-23-017739-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Canaccord Genuity LLC"},{"label":"Effective","value":"2023-06-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}